Hua Medicine (Shanghai) Ltd. (HUMDF)
Hua Medicine (Shanghai) Ltd. operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Shanghai, SH, CN. The stock last traded at $0.30, up 0.00% on the session, giving a market capitalisation of $303.2M. On trailing twelve-month figures it carries a trailing P/E of -16.82, a net margin of -16.5%. Its beta of 0.80 implies it has historically moved less than the broad market.
Hua Medicine (Shanghai) Ltd., a biopharmaceutical enterprise established in 2011 and headquartered in Beijing, China, specializes in the clinical development of novel therapeutic solutions, with a primary focus on addressing diabetes within the Chinese market. Its lead asset, Dorzagliatin (also known as HMS5552), is an orally administered medication designed for Type 2 Diabetes. The company is also advancing various combination therapies involving Dorzagliatin for T2D, including pairings with Metformin, Sitagliptin, and Empagliflozin, all of which are currently undergoing Phase I clinical trials. Furthermore, Hua Medicine explores the potential of Dorzagliatin in combination with Pioglitazone for Non-alcoholic steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for applications in late-stage Type 2 Diabetes and Type 1 Diabetes. Beyond its diabetes pipeline, the company is developing mGLUR5 as a potential treatment for levodopa-induced dyskinesia in Parkinson's disease patients.